Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00072631
Status:
COMPLETED
Last Update Posted:
2018-02-08
First Post:
2003-11-05
Brief Title:
Erlotinib Tarceva Trademark OSI-774 in Treating Patients With Advanced Non-Small Cell Lung Cancer
Sponsor:
OSI Pharmaceuticals
Organization:
Astellas Pharma Inc
Organization Data
Organization:
Astellas Pharma Inc
Class:
INDUSTRY
Study ID:
OSI-774-202
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
OSI Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None